EQT Life Sciences is pleased to announce that its portfolio company Endotronix has been acquired by Edwards Lifesciences.

EQT Life Sciences was the lead investor in Endotronix’s series D Financing, investing from its LSP Health Economics Fund 2. Endotronix is a leader in heart failure management solutions. In June 2024 it received approval for Cordella, an implantable pulmonary artery pressure sensor that allows for early, targeted therapeutic intervention. On August 19 th , the acquisition was approved by the regulatory authorities in the US.

Find the pre-regulatory approval press release here.